

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>3</sup> : <b>A61K 9/22, 31/485</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 83/ 03197</b> (43) International Publication Date: 29 September 1983 (29.09.83)</p>
<p>(21) International Application Number: PCT/US83/00333 (22) International Filing Date: 14 March 1983 (14.03.83) (31) Priority Application Numbers: 358,820 464,110 (32) Priority Dates: 16 March 1982 (16.03.82) 4 February 1983 (04.02.83) (33) Priority Country: US (71) Applicant: THE ROCKEFELLER UNIVERSITY [US/ US]; 1230 York Avenue, New York, NY 10021 (US). (72) Inventors: KREEK, Mary, Jeanne ; 1161 York Avenue, Apartment 12L, New York, NY 10021 (US). FISH- MAN, Jack ; 867 Park Avenue, Apartment 5N, New York, NY 10021 (US). (74) Agents: SCOBEEY, Robert et al.; Wyatt, Gerber, Shoup, Scobey &amp; Badie, 261 Madison Avenue, New York, NY 10016 (US).</p>		<p>(81) Designated States: AT (European patent), BE (Euro- pean patent), CH (European patent), DE (European patent), FR (European patent), GB (European pa- tent), JP, LU (European patent), NL (European pa- tent), SE (European patent).  Published <i>With international search report.</i> <i>With amended claims and statement.</i></p>
<p>(54) Title: METHOD FOR CONTROLLING GASTROINTESTINAL DYSMOTILITY</p> <p>(57) Abstract</p> <p>Method for controlling gastrointestinal dysmotility in humans by administration of opioid antagonists.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	LI	Liechtenstein
AU	Australia	LK	Sri Lanka
BE	Belgium	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SE	Sweden
FR	France	SN	Senegal
GA	Gabon	SU	Soviet Union
GB	United Kingdom	TD	Chad
HU	Hungary	TG	Togo
JP	Japan	US	United States of America
KP	Democratic People's Republic of Korea		

METHOD FOR CONTROLLING GASTROINTESTINAL DYSMOTILITYDESCRIPTION OF THE PRIOR ART

Gastrointestinal dysmotility affects many humans and is  
5 associated with various clinical signs and syndromes. Hypomotility is associated with chronic constipation, obstipation, idiopathic abdominal distention, abdominal pain, abdominal cramps, irritable bowel syndrome, non-tropical sprue, megacolon associated with hypothyroidism, pseudo-obstruction of the gastrointestinal  
10 tract, colitis, hypomotility of the colon associated with diabetes mellitus, adult onset Hirschsprung's disease, neurological disorders, myopathic disorders, geriatric hypomotility disorders, jejunal-ileal bypass with secondary megacolon, hypomotility associated with cancer chemotherapy, hypomotility associated with  
15 severe burns and other major stresses, hypomotility associated with syndromes of depression, post-operative intestinal distension, and other pathological conditions. Gastrointestinal hypomotility disorders also include other disorders of esophageal and gastric-motility and gastric emptying disorders such as  
20 diabetic gastric paresis, scleroderma and other disorders. Idiopathic constipation is a major health problem which affects many individuals. Millions of persons utilize laxatives, stool softeners, fiber preparations, mineral oil, gas absorbants, suppositories or enemas on a continuous basis. Partial  
25 hypomotility is a major feature of several defined gastrointestinal disorders.



-2-

Hypomotility is often associated with recurring bouts of hypermotility, the so-called intermittent hypomotility-hypermotility syndrome. Clinical manifestations of this affliction include alternate bouts of constipation and diarrhea, abdominal  
5 distention, pains and cramps, ileitis, regional enteritis, generalized irritable bowel syndrome, irritable colon syndrome, ulcerative and other forms of colitis.

Opioid antagonists are a well recognized class of chemical agents. They have been described in detail in the scientific  
10 and patent literature.

Pure opioid antagonists are agents which specifically reverse the effects of opioid agonists, bind to specific opioid receptors but have no opioid agonist activity.

This invention is concerned with the use of pure opioid  
15 antagonists in contrast to opioid agonists and agents that manifest mixed agonist-antagonist activities such as pentazocine, buprenorphine and others.

#### THE INVENTION

20 It has now been discovered that human disorders related to gastrointestinal dysmotility in humans can be improved, thereby alleviating the above noted illnesses, by administration of therapeutically effective amounts of pure opioid antagonists such as naloxone, naltrexone, nalmeffene and related compounds.

25 The pharmaceutically active product will normally be administered orally or parenterally. In some cases both routes may be employed either sequentially or simultaneously. The dosage regimen which has been found to be most effective is about 2 to



-3-

70 mg per day. The preferred dosage for oral administration is about 10 to 50 mg per day, and for parenteral administration about 10 to 70 mg per day. For sustained release forms of the medicament, either oral or parenteral dosage forms are useful which deliver 10 to 50 mg per day. Of course sustained release forms can be prepared which will deliver proportional amounts over selected periods of time, for example 4, 6 or 12 hours. These quantities, irrespective of the method or route of administration selected, appear to provide optimum relief for adults in the 60 to 70 kg weight class. The attending physician may choose to vary the defined quantities depending on such factors as the condition being treated, and the age, weight, and general physical condition of the patient.

The principal and preferred compounds which are the subject matter of this invention are naloxone, naltrexone and nalmeffene. These compounds are known narcotic antagonists. They are generally recognized as pure opioid antagonists and will be so regarded for purposes of this description. Naltrexone, however, has been described as having slight agonistic activity. Wikler, A., Int. J. of the Addictions 12(7) 869, 1977.

It should be noted, and is here emphasized, that the opioid antagonists as used in this invention are not used to neutralize the effect of opioid agonists such as narcotic drugs. They are used to treat clinical gastroenterologic disorders in which intestinal dysmotility is a major component. For such use they may be employed to treat intermittent or prolonged periods of hypomotility or intermittent hypomotility-hypermotility.



-4-

It has now been discovered that hypomotility arises from relative or absolute excess of one or more of the endogenous opioids at the intestinal level, in the brain or at both sites, or from abnormal binding of those endogenous opioids to their specific receptors in the intestine and/or brain, thereby causing inhibition of propulsive intestinal contractions. The use of pure opioid antagonists in accordance with this invention restores normal endogenous opioid balance and alleviates dysmotility problems.


Some humans, such as those suffering from chronic constipation, are affected with chronic hypomotility. Some individuals may suffer from hypermotility at one time and hypomotility another. As indicated above, the effect of the therapeutic agents of this invention when used as described herein is to restore the balance between available and bound opiate receptor sites thereby to restore normal motility as evidenced by relief of constipation, relief of abdominal distention or pain as illustrated in the examples.

Naloxone, naltrexone and nalmeferene are representatives of known classes of compounds which are pure opioid antagonists. The compounds of the class are derivatives of morphine and codeine.

Nalmeferene is typical of one useful class of compounds which are described together with their method of preparation in United States Patent 3,896,226 which was issued on July 22, 1975. The compounds are morphine or codeine derivatives which may be represented by the formula:



-5-



5  
10 wherein R is allyl or cyclopropylmethyl, R<sub>1</sub> is hydrogen or hydroxy and R<sub>2</sub> is hydroxy or methoxy.

Typical compounds within the scope of the formula include:

- a. 6-methylene-6-desoxy-N-allyl-14-hydroxydihydronor-morphine.
- b. 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihy-  
15 dronormorphine.
- c. 6-methylene-6-desoxy-N-cyclopropylmethyl dihydronor-morphine.
- d. 6-methylene-6-desoxy-N-allyl-dihydronormorphine.
- e. 6-methylene-6-desoxy-N-allyl-dihydronorcodeine.
- 20 f. 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihy-dronorcodeine.
- g. 6-methylene-6-desoxy-N-allyl-14-hydroxydihydronor-codeine.

Compound b is nalmeffene.

25 The compounds are prepared by reaction of the appropriate 6-keto starting compound with excess triphenylphosphomethylene followed by reaction with an allyl or cyclopropylmethyl halide,






-6-

suitably the bromide or chloride. If the starting compound is a 3-hydroxy compound, i.e., a morphine derivative, the final product can be converted to a codeine derivative by reaction with diazomethane to convert the hydroxyl group to a methoxyl moiety.

5 Other morphine derivatives which may be employed in the practice of the invention as well as methods for their preparation are described in United States Patents 3,254,088 and 3,332,950. They may be represented by the formula:



wherein  $R_3$  is allyl, 3'-methyl-2'-butenyl, cyclopropylmethyl or cyclobutylmethyl.

The compounds may be prepared by reaction of a selected 14-hydroxy starting compound with a suitable organic halide  
20 such as 1-bromo-3-methyl-2-butene, allyl bromide or the corresponding chlorides.

Typical compounds within the scope of the foregoing formula include:

- a. N-allyl-14-hydroxydihydronormorphinone.
- 25 b. N-cyclopropylmethyl-14-hydroxydihydronormorphinone.
- c. N-cyclobutylmethyl-14-hydroxydihydronormorphinone.
- d. N-(3'-methyl-2'-butenyl)-14-hydroxydihydronormorphinone.





-7-

The first named compound is naloxone. The second is naltrexone.

A third class of pure antagonists useful in this invention is described along with methods of preparation in United States

Patent 3,320,262. The compounds are represented by the formulas shown below in which the second formula represents dihydro compounds:



wherein  $R_4$  is methoxy or hydroxy,  $R_5$  is hydrogen or hydroxy and  $R_6$  is hydrogen, methyl, ethyl, propyl, allyl or benzyl.

Typical compounds within the scope of the formula include:

- a. N-cyclopropylmethyl-nor-14-hydroxycodeinone-6-carboxymethyloxime.



-8-

- b. N-cyclopropylmethyl-nor-codeinone-6-carboxymethyloxime.
- c. N-cyclopropylmethyl-nor-14-hydroxymorphinone-6-carboxy-methyloxime.
- d. N-cyclopropylmethyl-nor-morphinone-6-carboxymethyloxime methylester.
- e. N-cyclopropylmethyl-nor-14-hydroxydihydrocodeinone-6-carboxy-methyloxime.
- f. N-cyclopropylmethyl-nor-14-hydroxydihydrocodeinone-6-carboxy-methyloxime methylester.
- g. N-cyclopropylmethyl-nor-dihydrocodeinone-6-carboxy-methyloxime methylester.
- h. N-cyclopropylmethyl-nor-14-hydroxydihydromorphinone-6-carboxy-methyloxime methylester.
- i. N-cyclopropylmethyl-nor-dihydromorphinone-6-carboxy-methyloxime methylester.

The compounds are prepared by reaction of the selected ketone starting compound with a suitable organic halide as described above, followed by reaction of the N-substituted compounds with a selected ester of carboxymethoxyl amine.

- All of the compounds described above can be utilized in the form of pharmaceutically acceptable salts. Pharmaceutically acceptable salts are salts which are free of toxicity or other therapeutically harmful or undesirable effects. These include, for example, such salts as the hydrochloride, hydrobromide, neutral and acid fumarate and maleate, teraphthalate, ethane sulfonate, oxalate and bitartrate.

Water-soluble salts with volatile acids (e.g. hydrochloric



and acetic acid) can be prepared by adding an aqueous solution of slightly more than one equivalent of the acid to an aqueous dispersion of the base and evaporating the solution thus formed under reduced pressure. The residue can then be recrystallized.

- 5 Salts of non-volatile inorganic acids (e.g. orthophosphoric acid) can be prepared by adding the stoichiometric amount of the acid to an aqueous dispersion of the base and treating the resulting solution in the same way. Salts of organic acids which are difficultly soluble in water (e.g. the benzoate) can be prepared by reacting the acid and the base in equivalent amounts in  
10 ethyl alcohol medium and evaporating the solution.

- For ease of administration it is, of course, preferred to treat patients orally. Surprisingly, as is illustrated herein-  
after, naloxone, which has been art recognized as being poorly  
15 absorbed when given perorally is nevertheless active at local intestinal sites and effective for the indications mentioned above when administered orally. In the event that the patient is unable to cooperate, is kept in a "nothing by mouth" status, if there is an intransigent blockage of the gastrointestinal  
20 tract, or if antagonist activity at the brain or at other systemic sites is desired, the route of choice will be the parenteral route.

- The principal aspects of the invention, then, are the use of certain known compounds to achieve control of intestinal  
25 motility. The compounds may be used alone or in association with selected pharmaceutical carriers in the form of pharmaceutical compositions containing effective amounts of the active agents.



-10-

The compositions may be administered parenterally or by various non-parenteral routes, primarily oral, but also by buccal, sublingual, rectal and transdermal routes. The compositions may be prepared for relatively rapid absorption or in sustained release forms.

For buccal and sublingual administration the active ingredient can be formulated in tablet form with water soluble binding agents such as lactose or other palatable carbohydrates.

For rectal administration suppositories or inserts containing the active ingredient dispersed in such reagents as cocoa butter, petroleum, or other natural lubricant or in a synthetic emollient such as polyethylene glycol 1000 or polyethylene glycol 4000.

Transdermal administration will normally be from a sustained release preparation which may be applied as a patch or from a gauze applied to the skin.

The preferred method of administering the active agents of this invention is from sustained release forms since this is most convenient for patients, and avoids the necessity of constant clock watching or interruption of normal daily activities. A number of compositions suitable for such preparations are known and can be used in the practice of this invention. As aforesaid, the dosage forms can be prepared to deliver 10 to 50 mg of active ingredient per day divided over selected time intervals, for example 4, 6, 12 or even twenty-four hours.

One convenient procedure is to formulate the selected motility control agent in a time disintegrating tablet or peller



-11-

coated with various thicknesses of known materials such as carnauba wax, cellulose esters and ethers, fats, keratin, gluten or various natural or synthetic esters. Tablets in which the motility control agent is contained in a slowly dissolving core  
5 such as a core of stearic acid or castor oil are useful. Mixed release granule tablets comprising mixtures of the drug itself and the drug in separate particles coated with materials which dissolve at different rates such as dehydrogenated castor oil or fatty acids can also be employed. Alternatively the active  
10 material can be bound to an ion exchange resin such as sulfuric acid type cation exchange resin.

The presently preferred sustained release forms of this invention are those in which the active agent is carried through the gastrointestinal tract in a mixed polymer carrier. The  
15 carrier slowly erodes during transport so that increments of the opioid antagonist may be released for attachment to receptor sites.

In these forms, the principal carrier is a mixed, hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to  
20 four carbon atoms and at least one is propyl or butyl. This polymer functions as a drug release retardant. Cellulose derivatives which are substituted with two different alkyl groups are preferred since there is less tendency for such polymers to crystallize. The polymers are prepared by standard alkoxyla-  
25 tion reactions. In case two different alkyl groups are to be substituted, concurrent or successive reactions may be employed. Generally, with such mixed substituents there will be about 50%



-12-

of each substituent. The presently preferred polymer is propyl hydroxymethyl cellulose.

The cellulose derivative is normally hydrated to a degree of from about 5% to 25% by weight, preferably 10% to 20%. A degree of hydration of 15% by weight is especially preferred since it is readily achieved, and provides sustained release forms with excellent properties.

To prevent the cellulose polymer from crystallizing and thereby reducing the rate at which the active agent is released, an anticrystallinity agent is added. The function of the agent is to prevent the cellulose polymer from achieving a degree of regularity at which it will crystallize. The presently preferred anticrystallinity reagents are polyalkylene oxides, such as polyethylene oxide or other pharmaceutically acceptable analogues. The molecular weight of the oxide may vary from about 100,000 to 10 million with 4 to 5 million being preferred because of ready availability, ease of compounding and efficiency for preventing crystallization. Normally the amount of such agent added will be from about 15% to 30% by weight so that the weight of cellulose product will be from about 70% to 85%.

The polymer and selected active agent or agents are compounded, to form tablets or other standard dosage forms in conventional equipment with any of a number of anti-stick or releasing agents such as magnesium stearate or talc. The amount employed is not critical and normally ranges from about 0.5% to 2% by weight.



-13-

The sustained release dosage forms can be formulated to contain any desired quantity of active agent. Typically, a tablet or other form will contain from about 5% to 20% active ingredient and 80% to 95% carrier. As indicated above, they may be prepared to release the selected quantities of opioid antagonist over time periods of, for example, from 4 to 12 hours.

In the foregoing discussions, all quantities given on a by weight basis are based on the total weight except the degree of hydration of the cellulose derivative which is based on the weight of the derivative.

In short, the motility control agents of this invention can be administered in any of a wide variety of forms including tablets, capsules, lozenges, suppositories, emulsions, isotonic solutions and the like. They can be formulated for immediate absorption or for sustained release.

The following non-limiting examples are given by way of illustration only.

#### EXAMPLE 1

A female with a history of chronic constipation for a period of over twenty years, requiring daily use of large doses of laxatives plus frequent enemas, was admitted to the research hospital on day one at approximately 4:00 p.m. She was given a standard laxative regimen documented to be inadequate to effect a spontaneous bowel movement, and placed on a high residue diet.





-14-

During the first 24 hours she was treated with a placebo (Infusion A) according to the following schedule:

- 4 p.m.-5 p.m. 1) Dextrose and water 250 cc over 1 hr.  
5 p.m.-12 midnight 2) Saline 250 cc over 7 hrs.  
5 12 midnight-8 a.m. 3) Dextrose and water 250 cc over 8 hrs.  
8 a.m.-4 p.m. 4) Dextrose and water 250 cc over 8 hrs.  
1250 cc over 24 hrs.

On day two at 4:00 p.m. the placebo was terminated and the patient was treated intravenously with naloxone according to the following schedule.

- 4pm-5pm 1) Dextrose & Water 250 cc + 1.6mg Naloxone in 1 hr.  
5pm-12 midnight 2) Saline 250 cc + 8.4mg Naloxone in 7 hrs.  
12 midnight-8am 3) Dextrose & Water 250 cc + 9.6mg Naloxone in 8 hrs.  
8am-4pm 4) Dextrose & Water 500 cc + 9.6mg Naloxone in 8 hrs.  
1250 cc + 29.2mg Naloxone in 24 hrs

15

At 4:00 p.m. on day three the parenteral administration was discontinued and the dosage regimen was changed to oral administration of 3.6 mg of naloxone in synthetic grape juice every three hours for three days, omitting treatment only when the patient was sleeping. The total dosage per day was 21.6 mg.

20

During the five days that the patient was under hospital care the stools were collected and weighed. The results were as follows:



-15-

STOOL WEIGHT GRAMS

<u>Day</u>	<u>Wet Weight</u>	<u>Dry Weight</u>
1	452	41
2	649	52
5 3	985	77
4	997	77
5	806	65

Samples of the patient's blood and urine were collected each day and subjected to analysis. No adverse effects were observed.

The experiment was conducted as a single blind. The patient was not aware of whether she was receiving a placebo or the active agent.

EXAMPLE II

A second patient with a history of over twenty years of chronic constipation, intractable to laxatives, who for the past several months was only relieved by enema treatment was admitted to the hospital and placed on a high residue diet.

She was then treated in a manner similar to the patient of Example I, but with no laxatives or emenagoga given, in accordance with the following schedule:

<u>Day</u>	<u>Treatment</u>
1	29.2 mg naloxone, intravenous
2	placebo, oral
25 3	14.4 mg naloxone, oral
4	21.6 mg naloxone, oral
5	21.6 mg naloxone, oral
6	7.2 mg naloxone, oral



-16-

<u>Day</u>	<u>Treatment</u>
7	placebo, oral
8	placebo, oral
9	placebo, oral

- 5        The patient's stools were collected and weighed each day with the following results:

<u>STOOL WEIGHT GRAMS</u>			
	<u>Day</u>	<u>Wet Weight</u>	<u>Dry Weight</u>
	1	84	18.5
10	2	none	-
	3	35	8.2
	4	125	66.4
	5	230	82.4
	6	34	12.1
15	7	none	-
	8	43	12.2
	9	none	-

No adverse effects were noted by clinical examinations, blood or urine analysis.

- 20        The following tables summarize the results which were achieved with additional patients treated with nalaxone following the general procedures of Examples I and II. Substantially the same results will be achieved with naltrexone, nalmeferne and other compounds within the scope of the foregoing formulas.

- 25        The tables set forth the significant details and results of a number of studies conducted with different patients suffering from various forms of intestinal dysmotility. For example,



-17-

Table 1 reports the results of five separate studies, three in-patient and two outpatient, on the same patient at the research hospital. The first study was of two days duration. The lengths of subsequent studies are as indicated.

- 5        The reports Tables 1 to 5 are for patients with chronic constipation. Those in Tables 6, 7 and 8 are for patients with irritable bowel syndrome. Tables 9 and 10 are summaries.

10



-18-

TABLE 1

Patient Number 1  
A.O., a 53 year old female

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#1 (inpat- ient)	i.v.	1	P	-	452	41	1.8	No change
		2	A	29.2	649	52	3.0	Marked improvement
#2 (inpat- ient)	p.o.	1	A	21.6	985	77	4.7	Marked improvement
		2	A	21.6	997	77	3.3	Marked improvement
		3	A	21.6	806	65	2.4	Marked improvement
#3 (outpat- ient)	p.o.	1	A	21.6				Average day
		2	A	21.6				Better than average day
		3	A	21.6				Much better than average day
		4	P	-				Average day
		5	P	-				Bad day
		6	P	-				Bad day



-19-

TABLE 1 (continued)

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#4 (inpat- ient)	i.v.	1	neither	-	336	15	2.6	
		2	A	29.2	775	199	5.7	
		3	A	29.2	859	212	4.1	
#5 (outpat- ient)		1	A	21.6				Much better than average
		2	A	21.6				Much better than average
		3	A	21.6				Much better than average
		4	P	-				Average (diarrhea)
		5	P	-				Worse than average



-20-

TABLE 2

Patient Number 2  
B.K., a 30 year old female

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#1	-	1	neither	0				
		2	A	29.2	84	18.5	3.6	
		3	P	0	-	-	-	No stool
#2	-	1	A	14.4	35	8	1.1	
		2	A	21.6	125	66	5.9	
		3	A	21.6	230	82	9.0	
		4	A	7.2	34	12	0.8	
		5	P	0	-	-	-	No stool
		6	P	0	43	7	0.9	
		7	P	0	-	-	-	No stool
		8	P	0	30	7	0.8	
		9	-	0	37	10	0.9	



-21-

TABLE 3

Patient Number 3  
J.P., a 39 year old male

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#1	i.v.	1	A	29.2	-	-	-	No stool
		2	P	-	-	-	-	No stool
		3	-	-	-	-	-	No stool
		4	-	-	-	-	-	No stool
		5	-	-	-	-	-	No stool
#2	p.o.	1	-	-	-	-	-	No stool
		2	-	-	-	-	-	No stool
		3	-	-	-	-	-	No stool
		4	-	-	-	-	-	No stool
		5	A	21.6	-	-	-	No stool





-22-

TABLE 3 (continued)

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Rectal Wet Wt. (gm)	Rectal Dry Wt. (gm)	Rectal Fat (%)	Symptoms, Signs, Comments
		6	A	21.6	1	1	1	No stool
		7	A	21.6	1	1	1	No stool
		8	P	1	1	1	1	No stool
		9	P	1	1	1	1	No stool
		10	P	1	1	1	1	No stool

TABLE 4

Patient Number 7  
B.B., a 65 year old female

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#1 (in- patient)	i.v.	1	A	29.2	166	59	-	Cramps; improvement Spontaneous passage of stool
		2	P	-	205	42	-	Average; digital removal of stool
#2 (in- patient)	p.o.	1	A	21.6	-	missing	-	No stool
		2	A	21.6	238	35	-	Improvement; "natural easy BM's"
		3	A	21.6	262	35	-	Marked improvement; spontaneous "natural BM's"
		4	A	21.6	145	20	-	Marked improvement; spontaneous "natural BM's"
		5	P	-	265	23	-	Marked improvement; spontaneous "natural BM's"
		6	P	-	299	36	-	Marked improvement; spontaneous "natural BM's"
		7	P	-	166	38	-	Less improvement; less BM; still spontaneous

-24-

TABLE 4 (continued)

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#3 (in- patient)	i.v.	8	P	1	105	11	-	BM only with digital removal; back to average
		9	P	1	1	1	-	No BM even after attempt at digital removal
		1	P	1	1	1	-	
		2	P	1	135	17	-	Removal by digital manipulation
		3	A	29.2	1	1	-	
		4	A	29.2	183	24	-	Spontaneous BM; some of feces lost because of sudden urge to pass BM



TABLE 5

Patient Number 8  
H.D., a 71 year old male

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Rectal Wet Wt. (gm)	Rectal Dry Wt. (gm)	Rectal Fat (%)	Symptoms, Signs, Comments
#1	i.v.	1	P	-	144	12	-	
		2	A	29.2	281	17	-	Marked improvement
#2	p.o.	1	A	21.6	135	7	-	Marked improvement
		2	A	21.6	134	14	-	Marked improvement
		3	A	21.6	476	29	-	Marked improvement
		4	P	-	-	-	-	Spontaneous BM; but feces lost by patient because of sudden urge to pass BM
		5	P	-	554	26	-	Improvement
		6	P	-	114	9	-	Strain to pass stool

-25-



-29-

TABLE 6 (continued)

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Rectal Wet Wt. (gm)	Rectal Dry Wt. (gm)	Rectal Fat (%)	Symptoms, Signs, Comments
		8	P	1				Abdominal pain; some distention; slight improvement
		9	P	1				Distention; no pain; slight improvement



TABLE 7

Patient Number 5  
J.B., a 19 year old female

Study	Route of Administration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#1 (in-patient)	i.v.	1	A	29.2	61	14	2.6	Less distention; better than average day
		2	P	-	648	204	5.7	Less distention; better than average day
		1	A	10.8	253	75	0.8	Less distention
#2 (out-patient)	p.o.	2	A	21.6				Marked improvement; spontaneous BM
		3	A	21.6				Spontaneous BM; some distention
		4	P	-				Distention; pain; cramps; marked deterioration
#3 (in-patient)	i.v.	5	P	-				Spontaneous BM; some pain; distention
		6	P	-				Distention; spontaneous BM
		1	P	-	12	1		No change
		2	A	29.2	96	31		Much less distention; spontaneous passage of multiple soft BM

-30-



TABLE 7 (continued)

Study	Route of Adminis- tration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#4 (out- patient)	p.o.	1	A	21.6				3 BM passed; no pain; no distention
		2	A	21.6				3 BM soft passed; no pain, no distention
		3	A	21.6				2 BM soft passed; some cramps; no distention
		4	P	-				Small hard BM passed; distention
		5	P	-				2 small BM; pain; distention
		6	P	-				2 small BM; pain; distention

-31-



TABLE 8

Patient Number 6  
A.S., a 66 year old male

Study	Route of Administration	Study Day	Active Compound or Placebo	Total 24 Hour Dose (mg)	Fecal Wet Wt. (gm)	Fecal Dry Wt. (gm)	Fecal Fat (%)	Symptoms, Signs, Comments
#1 (in-patient)	i.v.	1	A	29.2	-	-	-	No BM; marked improvement with decreased pain and distention
		2	P	-	21	4	1.6	BM small; decreased pain and distention
#2 (out-patient)		1	A	18.0	60	14	2.1	Spontaneous BM; no distention; marked improvement
		2	A	21.6	44	6	2.3	Spontaneous BM; no distention; marked improvement
		3	A	21.6				No BM; no pain or distention
		4	A	21.6				Spontaneous BM; no symptoms
		5	A	21.6				No stool; no symptoms
		6	A/P	3.6				Spontaneous BM; no symptoms
		7	P	-				No stool; average day
		8	P	-				One BM; better than average day
		9	P	-				No stool; average day



TABLE 9

Chronic Constipation Patients

Patient Initials	Patient Number	Age	Sex	Diagnosis	Onset of Symptoms	No. of Inpatient Studies	No of Out- patient Studies (all P.O.)	Outcome
A.O.	1	53	F	Non-tropical sprue	more than 40 years	3 (2 iv; 1 po)	2	5 successful trials
B.K.	2	39	F	Idiopathic con- stipation	more than 20 years	2 (1 iv; 1 po)	0	2 successful trials
J.P.	3	39	M	Idiopathic con- stipation	about 10 years	2 (1 iv; 1 po)	0	No successful trials
B.B.	7	65	F	Idiopathic con- stipation	more than 50 years	3 (2 iv; 1 po)	1	2 successful trials; 1 probably successful trial
H.D.	8	77	M	Geriatric type idiopathic constipation	about 8 years	2 (1 iv; 1 po)	0	1 successful trial; 1 probably successful trial

-34-

TABLE 10  
Irritable Bowel Syndrome Patients

Patient Initials	Patient Number	Age	Sex	Onset of Symptoms	Number of Inpatient Studies	Number of Outpatient Studies (all P.O.)	Outcome
B.S.	4	68	M	More than 40 years	1 i.v.	3	Successful
J.B.	5	19	F	More than 10 years	2 i.v.	2	Successful
A.S.	6	66	M	About 5 years	1 i.v.	1	Successful



-35-

The following formulations illustrate procedures which can be employed to produce a variety of dosage forms of the active ingredients of this invention. The active ingredient in each formulation is naloxone. It could be naltrexone, nalmeferone or any of the other compounds of this invention.

TABLET

		<u>Mg Tablet</u>
1)	Oral form: Naloxone hydrochloride	12
	Starch	50
10	Lactose	75
	Magnesium stearate	2
	Stearic acid	5

The compound, a portion of the starch and the lactose are combined and wet granulated with starch paste. The wet granulation is placed on trays and allowed to dry overnight at a temperature of 45° C. The dried granulation is comminuted in a comminutor to a particle size of approximately 20 mesh. Magnesium stearate, stearic acid, and the balance of the starch are added and the entire mix blended prior to compression on a suitable tablet press. The tablets are compressed at a weight of 232 mg using a 11/12" punch with a balance of 4 kg. These tablets will disintegrate within a half hour according to the method described in USP XVI.

		<u>Mg Tablet</u>
2)	Naloxone	6
25	Microcrystalline cellulose	30
	Spray-dried lactose	60
	Colloidal silica	1
	Stearic acid	1



-36-

Screen the alkaloid to break up lumps and blend with microcrystalline cellulose. Add spray-dried lactose and blend. Finally add the stearic acid and colloidal silica; blend to obtain homogenous mixture. Compress using 9/32 in shallow concave  
5 punch.

CAPSULES

1)	Naloxone hydrochloride	10 mg.
	Lactose	45
10	Starch	45

The compound, a portion of the starch and the lactose are combined and wet granulated with starch paste. The wet granulation is placed on trays and allowed to dry overnight at a temperature of 45°C. The dried granulation is added to a hand  
15 gelatin capsule of the appropriate size.

2)	Naloxone	20 mg
	Sesame oil	90

The free base is mixed with sesame oil and encapsulated in a soft gelatin capsule of the appropriate size.

20

SUSTAINED RELEASE

## 1) Oral

Naloxone (12 mg) is included in a hydrophilic polymer matrix from which it will be gradually excluded following ingestion. The inclusion is accomplished by dissolving the free base  
25 in a suitable non-polar solvent from which it will be absorbed by the polymers. Removal of the solvent leaves the product



bound in the matrix from which it is released by water solution. Rates of delivery can be controlled by the hydrophilic character of the matrix which can be both non- or biodegradable as desired.

## 2) Oral

5           Naloxone (12mg) is mixed with sucrose and compounded into 1 mm diameter pellets to yield a total of 200 pellets. Fifty beads are used in the uncoated form. The remaining beads are divided into three equal parts and coated with stearic acid, palmitic acid and glycerol myristate in appropriate amounts to  
10 allow dissolution in the intestine over 4, 8 or 12 hours. The beads are encapsulated in an appropriate size hard gelatin capsule.

## PARENTERAL

15	1)	Naloxone hydrochloride	<u>Mg/cc</u> 10
		Methyl paraben	1.8
		Propyl paraben	0.2
		Water for injection	q.s.

The solution is prepared by first dissolving the parabens  
20 in hot water for injection, cooling to room temperature and dissolving the compound and sodium chloride. It is then filtered, using sterile technique, through a bacteriological filter (0.6 micron or smaller porosity), after which it is transferred into ampoules or multiple-dose vials.

25	2)	Naloxone	<u>Mg/cc</u> 10 or 20
		Ethanol	100
		Propylene-glycol	880



The solution is prepared by dissolving the naloxone in the alcohol and diluting with propylene glycol. It is then filtered using sterile techniques, through a bacteriological filter after which it is transferred into ampules or multiple dose vials.

5

SUSTAINED RELEASE

## 1) Parenteral

The hydrochloride salt of naloxone (20mg) is dissolved in an appropriate amount of ethanol. The solution is mixed with  
10 sesame oil (5:1 ratio) and heated at 45° under vacuum to remove the alcohol. The residue (drug in sesame oil) is transferred into individual or repeated dose ampoules.

## 2) Suppository

	<u>Percent</u>
Naloxone hydrochloride	4.06
15 Polyoxyethylene 1000 (approx M 1000)	80.14
Polyoxyethylene 4000 (approx M 4000)	15.00
Methyl paraben	.45
Propyl paraben	.05
Purified water USP	3.10

20 The HCl salt of the compound is dissolved in the water and added to a melted mixture of the polyoxyethylenes which are already combined with the parabens. This molten mixture is poured into suppository molds and cast into suppositories weighing 3 grams each. They are frozen to solidify and packaged into foil.

## 25 3) Tablet

A total of 65 gm 15% hydrated propyl hydroxymethyl cellulose and 24 gm polyethylene oxide (mw= 5,000,000) are mixed



together with 10 gm of naloxone hydrochloride in a uniform powdery slurry and 1 mg magnesium stearate is added. The mix is pressed into tablets at a pressure of 100 atm. Each of the tablets contains 10 mg naloxone. A tablet when orally administered  
5 delivers the naloxone over a period of 12 hours.

4) Tablet


Nalmefene tablets which are suitable for a sustained release delivery over 12 hour periods are prepared by mixing in the conventional manner 63 gm 15% hydrated propyl hydroxy-  
10 methyl cellulose and 24 gm polyethylene oxide (mw= 5,000,000) together with 12 gm of nalmefene hydrochloride in a uniform powdery slurry. The mix is pressed into tablets at a pressure of 100 atm, each of the tablets containing 12 mg nalmefene.



WHAT IS CLAIMED IS:

1. A method for the restoration of normal motility in a patient afflicted with an intestinal dysmotility which comprises the administration of an amount which is effective to restore motility of a compound represented by the formula:

10



wherein R<sub>3</sub> is 3'-methyl-2-buteneyl; allyl; cyclopropylmethyl; or cyclobutylmethyl and pharmaceutically acceptable salts thereof.

2. A method as in claim 1 wherein the method of administration is oral and the amount administered is from about 10 to about 50 mg per day.
3. A method as in claim 1 wherein the method of administration is parenteral and the amount administered is from about 10 to about 70 mg per day.
4. A method as in claim 1, 2 or 3 wherein the compound administered is naloxone.
5. A method as in claims 1, 2 or 3 wherein the compound administered is naltrexone.
6. A method as in claims 1, 2 or 3 where the result of the dysmotility is constipation.





7. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is irritable bowel syndrome.

8. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is constipation, and the compound administered is


5 naloxone.

9. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is constipation, and the compound administered is naltrexone.

10. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is irritable bowel syndrome and the compound administered is naloxone.

11. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is irritable bowel syndrome and the compound administered is naltrexone.

15 12. a method for the restoration of normal motility in a patient afflicted with intestinal dysmotility which comprises administration of an amount which is effective to restore normal motility of a compound represented by the formula:



20

25

wherein R is allyl or cyclopropylmethyl,  $R_1$  is hydrogen or hydroxy and  $R_2$  is hydroxy or methoxy and pharmaceutically acceptable salts thereof.

13. A method as in claim 12 wherein the method of administration is oral and the amount administered is from about 10 to 50 mg per day.

14. A method as in claim 12 wherein the method of administration is oral and the amount administered is from about 10 to 70 mg per day.

15. A method as in claims 12, 13 or 14 wherein the compound administered is nalmeferene.

16. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is constipation.

17. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is irritable bowel syndrome.

18. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is constipation, and the compound administered is nalmeferene.


19. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is irritable bowel syndrome and the compound administered is nalmeferene.

20. A method for the restoration of normal motility in a patient afflicted with intestinal dysmotility which comprises administration of an amount which is effective to restore motility of a compound represented by the formula:



-43-

5



and the corresponding dehydro compounds wherein  $R_4$  is methoxy or hydroxy,  $R_5$  is hydrogen or hydroxy, and  $R_6$  is hydrogen, methyl, ethyl, propyl, allyl and benzyl, and the pharmaceutically acceptable salts thereof.

21. A method as in claim 20 wherein the method of administration is oral and the amount administered is from about 10 to about 50 mg per day.

15 22. A method as in claim 20 wherein the method of administration is parenteral and the amount administered is from about 10 to about 70 mg per day.


23. A method as in claims 20, 21 or 22 wherein the result of the dysmotility is constipation.

20 24. A method as in claims 20, 21 or 22 wherein the result of the dysmotility is irritable bowel syndrome.



-44-

25. A sustained release formulation suitable for administering an opioid antagonist to a patient to restore normal intestinal utility, the antagonist being represented by the formula:



wherein  $R_3$  is 3'-methyl-2-butenyl; allyl; cyclopropylmethyl; or cyclobutylmethyl and including the pharmaceutically acceptable salts thereof; said formulation containing, based on the total weight, from about 5% to 20% of opioid antagonist and from 80% to 95% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them is propyl or butyl, and, based on the total weight, from 30% to 70% of a pharmaceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.

26. A formulation as in Claim 25 wherein the opioid antagonist is naloxone.

27. A formulation as in Claim 25 wherein the opioid antagonist is naltrexone.


28. A formulation as in Claim 25, 26 or 27 wherein the hydrated alkyl hydroxy cellulose is propyl hydroxynethyl cellulose.



-45-

29. A formulation as in Claim 25, 26, 27 or 28 in dosage unit form.

30. A sustained release formulation suitable for administering an opioid antagonist to a patient to restore normal intestinal utility, the antagonist being represented by the formula:



wherein R is allyl or cyclopropylmethyl, R<sub>1</sub> is hydrogen or hydroxy and R<sub>2</sub> is hydroxy or methoxy and including the pharmaceutically acceptable salts thereof; said formulation containing, based on the total weight, from about 5% to 20% of opioid antagonist and from 80% to 95% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them is propyl or butyl, and, based on the total weight, from 30% to 70% of a pharmaceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.


31. A formulation as in Claim 30 wherein the opioid antagonist is nalmeferene.

-46-

32. A formulation as in Claim 30 wherein the hydrated alkyl hydroxy cellulose is propyl hydroxymethyl cellulose.

33. A formulation as in Claim 30, 31 or 32 in dosage unit form.

5 34. A sustained release formulation suitable for administering an opioid antagonist to a patient to restore normal intestinal utility, the antagonist being represented by the formula:



and the corresponding dehydro compounds wherein  $R_4$  is methoxy or hydroxy,  $R_5$  is hydrogen or hydroxy, and  $R_6$  is hydrogen, methyl, ethyl, propyl, allyl and benzyl, and including pharmaceutically acceptable salts thereof; said formulation containing, based on

20 the total weight, from about 5% to 20% of opioid antagonist and from 80% to 85% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them

25 is propyl or butyl, and, based on the total weight, from 30% to

-47-

70% of a pharmaceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.

35. A formulation as in Claim 34 wherein the hydrated alkyl  
5 hydroxy cellulose is propyl hydroxymethyl cellulose.

36. A formulation as in claim 34 or 35 in dosage unit form.

37. A method for the restoration of normal motility in a patient afflicted with an intestinal dysmotility which is independent of prior administration of opioid agonists which comprises the  
10 administration of an amount of pure opioid antagonist which is effective to restore motility.


38. A sustained release formulation suitable for administering an opioid antagonist to a patient to restore normal intestinal motility comprising from 5% to 20% of an opioid antagonist and  
15 from 80% to 95% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them is propyl or butyl, and, based on the total weight, from 30% to 70% of a pharma-  
20 ceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.



## AMENDED CLAIMS

(received by the International Bureau on 09 August 1983 (09.08.83))

1. A method for the restoration of normal motility in a patient afflicted with an intestinal dysmotility which is independent of prior administration of opioid agonists which comprises the administration of an amount which is effective to restore motility of a compound represented by the formula:



- wherein  $R_3$  is 3'-methyl-2-butenyl; allyl; cyclopropylmethyl; or cyclobutylmethyl and pharmaceutically acceptable salts thereof.
2. A method as in claim 1 wherein the method of administration is oral and the amount administered is from about 10 to about 50 mg per day.
3. A method as in claim 1 wherein the method of administration is parenteral and the amount administered is from about 10 to about 70 mg per day.
4. A method as in claim 1, 2 or 3 wherein the compound administered is naloxone.
5. A method as in claims 1, 2 or 3 wherein the compound administered is naltrexone.
6. A method as in claims 1, 2 or 3 where the result of the dysmotility is constipation.



7. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is irritable bowel syndrome.


8. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is constipation, and the compound administered is  
5 naloxone.

9. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is constipation, and the compound administered is naltrexone.

10. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is irritable bowel syndrome and the compound administered is naloxone.

11. A method as in claims 1, 2 or 3 wherein the result of the dysmotility is irritable bowel syndrome and the compound administered is naltrexone.

12. A method for the restoration of normal motility in a patient afflicted with intestinal dysmotility which is independent of prior administration of opioid agonists which comprises administration of an amount which is effective to restore normal motility of a compound represented by the formula:



wherein R is allyl or cyclopropylmethyl, R<sub>1</sub> is hydrogen or hydroxy and R<sub>2</sub> is hydroxy or methoxy and pharmaceutically acceptable salts thereof.

13. A method as in claim 12 wherein the method of administration is oral and the amount administered is from about 10 to 50 mg per day.

14. A method as in claim 12 wherein the method of administration is oral and the amount administered is from about 10 to 70 mg per day.

15. A method as in claims 12, 13 or 14 wherein the compound administered is nalmeferene.

16. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is constipation.

17. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is irritable bowel syndrome.


18. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is constipation, and the compound administered is nalmeferene.

19. A method as in claims 12, 13 or 14 wherein the result of the dysmotility is irritable bowel syndrome and the compound administered is nalmeferene.

20. A method for the restoration of normal motility in a patient afflicted with intestinal dysmotility which is independent of prior administration of opioid agonists which comprises administration of an amount which is effective to restore motility of a compound represented by the formula:



25. A sustained release formulation suitable for administering an opioid antagonist to a patient to restore normal intestinal motility, the antagonist being represented by the formula:



10

wherein R<sub>3</sub> is 3'-methyl-2-butenyl; allyl; cyclopropylmethyl; or cyclobutylmethyl and including the pharmaceutically acceptable salts thereof; said formulation containing, based on the total weight, from about 5% to 20% of opioid antagonist and from 80% to 95% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them is propyl or butyl, and, based on the total weight, from 30% to 70% of a pharmaceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.

26. A formulation as in Claim 25 wherein the opioid antagonist is naloxone.


27. A formulation as in Claim 25 wherein the opioid antagonist is naltrexone.

28. A formulation as in Claim 25, 26 or 27 wherein the hydrated alkyl hydroxy cellulose is propyl hydroxymethyl cellulose.

-52-

29. A formulation as in Claim 25, 26, 27 or 28 in dosage unit form.

30. A sustained release formulation suitable for administering an opioid antagonist to a patient to restore normal intestinal motility, the antagonist being represented by the formula:




wherein R is allyl or cyclopropylmethyl, R<sub>1</sub> is hydrogen or hydroxy and R<sub>2</sub> is hydroxy or methoxy and including the pharmaceutically acceptable salts thereof; said formulation containing, based on the total weight, from about 5% to 20% of opioid antagonist and from 80% to 95% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them is propyl or butyl, and, based on the total weight, from 30% to 70% of a pharmaceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.

31. A formulation as in Claim 30 wherein the opioid antagonist is nalmeferene.

32. A formulation as in Claim 30 wherein the hydrated alkyl hydroxy cellulose is propyl hydroxymethyl cellulose.

33. A formulation as in Claim 30, 31 or 32 in dosage unit form.

34. A sustained release formulation suitable for administering an opioid antagonist to a patient to restore normal intestinal motility, the antagonist being represented by the formula:



and the corresponding dehydro compounds wherein  $R_4$  is methoxy or hydroxy,  $R_5$  is hydrogen or hydroxy, and  $R_6$  is hydrogen, methyl, ethyl, propyl, allyl and benzyl, and including pharmaceutically acceptable salts thereof; said formulation containing, based on the total weight, from about 5% to 20% of opioid antagonist and from 80% to 85% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them is propyl or butyl, and, based on the total weight, from 30% to

-54-

70% of a pharmaceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.

35. A formulation as in Claim 34 wherein the hydrated alkyl hydroxy cellulose is propyl hydroxymethyl cellulose.

36. A formulation as in claim 34 or 35 in dosage unit form.

37. A method for the restoration of normal motility in a patient afflicted with an intestinal dysmotility which is independent of prior administration of opioid agonists which comprises the administration of an amount of pure opioid antagonist which is effective to restore motility.

38. A sustained release formulation suitable for administration of a pure opioid antagonist to a patient to restore normal intestinal motility; said formulation containing, based on the total weight, from 5% to 20% of pure opioid antagonist and from 80% to 95% of a carrier, said carrier comprising a release agent together with from, based on the total weight, 70% to 30% of a hydrated alkyl hydroxy cellulose in which the alkyl groups contain up to four carbon atoms and at least one of them is propyl or butyl, and, based on the total weight, from 30% to 70% of a pharmaceutically acceptable polyalkylene oxide, the degree of hydration of the alkyl hydroxy cellulose being from 5% to 25% by weight based on its total weight.

39. A formulation as in Claim 37 wherein the hydrated alkyl hydroxy cellulose is propyl hydroxymethyl cellulose.

40. A formulation as in Claim 38 or 39 in dosage unit form.



## STATEMENT UNDER ARTICLE 19

New pages 40 to 42 and 44 to 47 replace the same numbered pages in the application presently on file.

The new pages are for the purpose of making the following changes in the claims:

Claims 1, 12 and 20: at line 2, in each instance insert "which is independent of prior administration of opioid agonists" after "dysmotility".

Claim 12, line 1: change "a" to "A".

Claims 25, 30 and 34: at line 3, in each instance change "utility" to read "motility".

Claim 38, lines 1 and 2: change "administering an" to "administration of a pure".


Claim 38, line 3: change "comprising" to "; said formulation containing, based on the total weight,".

Claim 38, line 3: change "an" to "pure".

Page 47 introduces new claims 39 and 40.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 8 3 / 0 0 3 3 3

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC <sup>3</sup>		
A61 K 9/22	A61 K 31/485	
US 424/ 19	US 424/260	
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>4</sup>		
Classification System	Classification Symbols	
US	424/19 424/260	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>5</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>		
Category *	Citation of Document, <sup>15</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
X	US, A 3,254,088 PUBLISHED 31 MAY 1966, LEWENSTEIN ET AL.	1-11, 25-29
X	US, A 3,320,262 PUBLISHED 16 MAY 1967, LEWENSTEIN ET AL.	20-24, 34-38
X	US, A 3,332,950 PUBLISHED 25 JULY 1967, BLUMBERG ET AL.	1-11, 25-29
X	US, A 3,896,226 PUBLISHED 22 JULY 1975, FISHMAN	12-19, 30-33
X	US, A 4,176,186 PUBLISHED 27 NOVEMBER 1979, GOLDBERG ET AL.	1-11, 25-29
X	US, A 4,272,541 PUBLISHED 9 JUNE 1981, KOTICK ET AL.	1-11, 25-29
X	US, A 3,344,029 PUBLISHED 26 SEPTEMBER 1967, BERGER	1-38
X	US, A 4,277,605 PUBLISHED 7 JULY 1981, BUYNISKI ET AL.	1-38
<p>* Special categories of cited documents: <sup>16</sup></p> <p>"A" document defining the general state of the art</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document cited for special reason other than those referred to in the other categories</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but on or after the priority date claimed</p> <p>"T" later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search <sup>1</sup>	Date of Mailing of this International Search Report <sup>2</sup>	
31+MAY 1983	15 JUN 1983	
International Searching Authority <sup>1</sup>	Signature of Authorized Officer <sup>10</sup>	
ISA/USA		



III

- |   |       |                                     |      |
|---|-------|-------------------------------------|------|
| X | US, A | 3,060,086 PUBLISHED 23 OCTOBER 1962 | 1-38 |
|   |       | KUETER                              |      |
| X | US, A | 3,214,341 PUBLISHED 26 OCTOBER 1965 | 1-38 |
|   |       | FEINSTONE                           |      |